• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Performance versus Risk Factor-Based Approaches to Coronary Artery Disease Screening in Waitlisted Kidney Transplant Candidates.基于风险因素和临床表现的冠状动脉疾病筛查策略在等待肾移植候选者中的应用比较。
Cardiorenal Med. 2021;11(3):140-150. doi: 10.1159/000516158. Epub 2021 May 25.
2
Physical Performance Testing in Kidney Transplant Candidates at the Top of the Waitlist.等待移植名单首位的肾移植候选人的体能测试。
Am J Kidney Dis. 2020 Dec;76(6):815-825. doi: 10.1053/j.ajkd.2020.04.009. Epub 2020 Jun 6.
3
Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.无症状性冠状动脉疾病在等待肾移植候选人中的筛查:成本-效用分析。
Am J Kidney Dis. 2020 May;75(5):693-704. doi: 10.1053/j.ajkd.2019.10.001. Epub 2019 Dec 4.
4
Trends in Coronary Artery Disease Screening before Kidney Transplantation.移植前冠状动脉疾病筛查的趋势。
Kidney360. 2021 Dec 9;3(3):516-523. doi: 10.34067/KID.0005282021. eCollection 2022 Mar 31.
5
Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease-A trial protocol for the CARSK study.加澳随机筛选肾移植候选者冠心病试验-CARSK 研究试验方案。
Am Heart J. 2019 Aug;214:175-183. doi: 10.1016/j.ahj.2019.05.008. Epub 2019 May 22.
6
CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates.CAD-LT 评分可有效预测肝移植候选者发生严重冠状动脉疾病的风险。
J Hepatol. 2021 Jul;75(1):142-149. doi: 10.1016/j.jhep.2021.01.008. Epub 2021 Jan 18.
7
Validation of a strategy to diagnose coronary artery disease and predict cardiac events in high-risk renal transplant candidates.一种用于诊断冠状动脉疾病并预测高危肾移植受者心脏事件的策略的验证
Coron Artery Dis. 2010 May;21(3):164-7. doi: 10.1097/MCA.0b013e328332ee5e.
8
Screening Transplant Waitlist Candidates for Coronary Artery Disease.筛查冠状动脉疾病的移植等待名单候选人。
Clin J Am Soc Nephrol. 2019 Jan 7;14(1):112-114. doi: 10.2215/CJN.10510918. Epub 2018 Dec 28.
9
Coronary Revascularization Versus Optimal Medical Therapy in Renal Transplant Candidates With Coronary Artery Disease: A Systematic Review and Meta-Analysis.冠状动脉疾病肾移植候选者的冠状动脉血运重建与最佳药物治疗:系统评价和荟萃分析。
J Am Heart Assoc. 2022 Feb 15;11(4):e023548. doi: 10.1161/JAHA.121.023548. Epub 2022 Feb 8.
10
Cardiorespiratory requirements and reproducibility of the six-minute walk test in elderly patients with coronary artery disease.老年冠心病患者六分钟步行试验的心肺需求及可重复性
Arch Phys Med Rehabil. 2004 Sep;85(9):1538-43. doi: 10.1016/j.apmr.2003.11.037.

引用本文的文献

1
Cardiac evaluation in patients awaiting kidney transplant-position statement of the Cardiological Society of India and Indian Society of Nephrology.印度心脏病学会和印度肾脏病学会关于等待肾移植患者心脏评估的立场声明
Indian Heart J. 2025 May-Jun;77(3):204-212. doi: 10.1016/j.ihj.2025.03.012. Epub 2025 Mar 25.
2
Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association: Endorsed by the American Society of Transplantation.新兴的肾和肝移植候选者冠心病筛查证据:美国心脏协会的科学声明:得到美国移植学会的认可。
Circulation. 2022 Nov 22;146(21):e299-e324. doi: 10.1161/CIR.0000000000001104. Epub 2022 Oct 17.

本文引用的文献

1
A propensity score-matched analysis indicates screening for asymptomatic coronary artery disease does not predict cardiac events in kidney transplant recipients.倾向评分匹配分析表明,对无症状冠状动脉疾病进行筛查并不能预测肾移植受者的心脏事件。
Kidney Int. 2021 Feb;99(2):431-442. doi: 10.1016/j.kint.2020.10.019. Epub 2020 Nov 7.
2
Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant.肾移植后的死亡:按时代和移植后时间分析。
J Am Soc Nephrol. 2020 Dec;31(12):2887-2899. doi: 10.1681/ASN.2020050566. Epub 2020 Sep 9.
3
Coronary Artery Disease Screening of Asymptomatic Kidney Transplant Candidates: A Web-Based Survey of Practice Patterns in the United States.无症状肾移植候选者的冠状动脉疾病筛查:美国基于网络的实践模式调查
Kidney Med. 2020 Jun 15;2(4):505-507. doi: 10.1016/j.xkme.2020.04.006. eCollection 2020 Jul-Aug.
4
Physical Performance Testing in Kidney Transplant Candidates at the Top of the Waitlist.等待移植名单首位的肾移植候选人的体能测试。
Am J Kidney Dis. 2020 Dec;76(6):815-825. doi: 10.1053/j.ajkd.2020.04.009. Epub 2020 Jun 6.
5
Management of Coronary Disease in Patients with Advanced Kidney Disease.晚期肾病患者的冠状动脉疾病管理。
N Engl J Med. 2020 Apr 23;382(17):1608-1618. doi: 10.1056/NEJMoa1915925. Epub 2020 Mar 30.
6
OPTN/SRTR 2018 Annual Data Report: Kidney.OPTN/SRTR 2018 年度数据报告:肾脏。
Am J Transplant. 2020 Jan;20 Suppl s1:20-130. doi: 10.1111/ajt.15672.
7
Fourth Universal Definition of Myocardial Infarction (2018).心肌梗死的第四次全球定义(2018年)。
Circulation. 2018 Nov 13;138(20):e618-e651. doi: 10.1161/CIR.0000000000000617.
8
A new approach to kidney wait-list management in the kidney allocation system era: Pilot implementation and evaluation.肾脏分配系统时代的新肾脏候补者名单管理方法:试点实施与评估。
Clin Transplant. 2018 Nov;32(11):e13406. doi: 10.1111/ctr.13406. Epub 2018 Oct 15.
9
Cardiorespiratory Fitness (Peak Oxygen Uptake): Safe and Effective Measure for Cardiovascular Screening Before Kidney Transplant.心肺适能(峰值摄氧量):肾移植前心血管筛查的安全有效指标。
J Am Heart Assoc. 2018 May 31;7(11):e008662. doi: 10.1161/JAHA.118.008662.
10
Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy.英国维持性肾脏替代治疗患者合并症调整死亡率下降。
Kidney Int. 2018 May;93(5):1165-1174. doi: 10.1016/j.kint.2017.11.020. Epub 2018 Feb 12.

基于风险因素和临床表现的冠状动脉疾病筛查策略在等待肾移植候选者中的应用比较。

Performance versus Risk Factor-Based Approaches to Coronary Artery Disease Screening in Waitlisted Kidney Transplant Candidates.

机构信息

Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

出版信息

Cardiorenal Med. 2021;11(3):140-150. doi: 10.1159/000516158. Epub 2021 May 25.

DOI:10.1159/000516158
PMID:34034263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8238860/
Abstract

INTRODUCTION

Current screening algorithms for coronary artery disease (CAD) before kidney transplantation result in many tests but few interventions.

OBJECTIVE

The aim of this study was to study the utility of 6-minute walk test (6MWT), an office-based test of cardiorespiratory fitness, for risk stratification in this setting.

METHODS

We enrolled 360 patients who are near the top of the kidney transplant waitlist at our institution. All patients underwent CAD evaluation irrespective of 6MWT results. We examined the association between 6MWT and time to CAD-related events (defined as cardiac death, revascularization, nonfatal myocardial infarction, and removal from the waitlist for CAD), treating noncardiac death and waitlist removal for non-CAD reasons as competing events.

RESULTS

The 6MWT-based approach designated approximately 45% of patients as "low risk," whereas a risk factor- or symptom-based approach designated 14 and 81% of patients as "low risk," respectively. The 6MWT-based approach was not significantly associated with CAD-related events within 1 year (subproportional hazard ratio [sHR] 1.00 [0.90-1.11] per 50 m) but was significantly associated with competing events (sHR 0.70 [0.66-0.75] per 50 m). In a companion analysis, removing waitlist status from consideration, 6MWT result was associated with the development of CAD-related events (sHR 0.92 [0.84-1.00] per 50 m).

CONCLUSIONS

The 6MWT designates fewer patients as high risk and in need of further testing (compared to risk factor-based approaches), but its utility as a pure CAD risk stratification tool is modulated by the background waitlist removal rate. CAD screening before kidney transplant should be tailored according to a patient's actual chance of receiving a transplant.

摘要

简介

目前,在进行肾移植前对冠状动脉疾病(CAD)进行的筛查算法导致了许多检查,但干预措施很少。

目的

本研究旨在研究 6 分钟步行测试(6MWT)作为一种基于办公室的心肺功能测试,在这种情况下用于风险分层的效用。

方法

我们招募了 360 名接近我们机构肾移植候补名单榜首的患者。所有患者均接受了 CAD 评估,无论 6MWT 结果如何。我们研究了 6MWT 与 CAD 相关事件(定义为心脏死亡、血运重建、非致命性心肌梗死和因 CAD 从候补名单中移除)之间的关联,将非心脏死亡和因非 CAD 原因从候补名单中移除作为竞争事件。

结果

基于 6MWT 的方法将约 45%的患者指定为“低风险”,而基于风险因素或症状的方法分别将 14%和 81%的患者指定为“低风险”。基于 6MWT 的方法与 1 年内 CAD 相关事件无显著相关性(亚比例风险比[ sHR]每 50m 为 1.00[0.90-1.11]),但与竞争事件显著相关(sHR 每 50m 为 0.70[0.66-0.75])。在一项伴随分析中,从考虑中去除候补名单状态,6MWT 结果与 CAD 相关事件的发生相关(sHR 每 50m 为 0.92[0.84-1.00])。

结论

与基于风险因素的方法相比,6MWT 将更少的患者指定为高风险且需要进一步检查(高风险且需要进一步检查),但作为一种纯粹的 CAD 风险分层工具,其效用受到候补名单去除率的调节。肾移植前的 CAD 筛查应根据患者接受移植的实际机会进行调整。